Jianmin Pharmaceutical GroupLtd Gestione

Gestione criteri di controllo 3/4

Jianmin Pharmaceutical GroupLtd Il CEO è Jun Wang, nominato in Sep2022, ha un mandato di 2.17 anni. possiede direttamente 0.23% delle azioni della società, per un valore di CN¥ 14.76M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.2 anni e 2.2 anni.

Informazioni chiave

Jun Wang

Amministratore delegato

CN¥891.4k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	2.2yrs
Proprietà del CEO	0.2%
Durata media del management	2.2yrs
Durata media del Consiglio di amministrazione	2.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Jun Wang (47 yo)

2.2yrs

Mandato

CN¥891,400

Compensazione

Mr. Jun Wang was Vice President of KPC Pharmaceuticals,Inc until September 08, 2020. He is Managing Director of Jianmin Pharmaceutical Group Co.,Ltd. He is Director and President of Jianmin Pharmaceutical...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jun Wang	President	2.2yrs	CN¥891.40k	0.23% CN¥ 14.8m
Chaoyang Cheng	Financial Director	2.2yrs	CN¥511.20k	0.055% CN¥ 3.6m
Zhenbo Hu	VP & Director	1.3yrs	CN¥210.40k	Nessun dato
Jie Zhou	Secretary	2.2yrs	CN¥408.80k	0.024% CN¥ 1.6m
Xuejun Pei	Vice President	2.2yrs	CN¥540.00k	0.12% CN¥ 7.8m
Zhijun Huang	Vice President	2.2yrs	CN¥540.00k	0.11% CN¥ 6.9m

2.2yrs

Durata media

49yo

Età media

Gestione esperta: Il team dirigenziale di 600976 è considerato esperto (durata media dell'incarico 2.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jun Wang	President	2.2yrs	CN¥891.40k	0.23% CN¥ 14.8m
Zhenbo Hu	VP & Director	1.3yrs	CN¥210.40k	Nessun dato
Qin He	Chairman	2.2yrs	CN¥2.10m	0.27% CN¥ 17.5m
Qijing Xiao	Chairman of the Supervisory Board	2.2yrs	Nessun dato	Nessun dato
Yunpei Guo	Independent Director	2.2yrs	CN¥90.00k	Nessun dato
Rong Pei	Director	2.2yrs	CN¥60.00k	Nessun dato
Liang Xu	Director	2.2yrs	CN¥60.00k	Nessun dato
Shuqu Li	Independent Director	2.2yrs	CN¥90.00k	Nessun dato
Hu Jian	Supervisor	2.2yrs	Nessun dato	Nessun dato
Li Chen	Supervisor	2.2yrs	Nessun dato	Nessun dato
Jingqiu Tang	Supervisor	2.2yrs	Nessun dato	Nessun dato
Zhi Yang	Independent Director	2.2yrs	CN¥90.00k	Nessun dato

2.2yrs

Durata media

53.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 600976 non è considerato esperto (durata media del mandato 2.2 anni), il che suggerisce un nuovo consiglio.

Jianmin Pharmaceutical GroupLtd Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Jianmin Pharmaceutical Group Co.,Ltd., Annual General Meeting, Apr 08, 2024

No independent directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.54 (vs CN¥1.07 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 24%

Jianmin Pharmaceutical Group Co.,Ltd. to Report Q3, 2024 Results on Oct 19, 2024

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2024 Results on Aug 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.65 in 1Q 2023)

Jianmin Pharmaceutical Group Co.,Ltd. to Report Q1, 2024 Results on Apr 20, 2024

Full year 2023 earnings released: EPS: CN¥3.41 (vs CN¥2.68 in FY 2022)

Jianmin Pharmaceutical Group Co.,Ltd., Annual General Meeting, Apr 08, 2024

Investor sentiment deteriorates as stock falls 16%

Jianmin Pharmaceutical Group Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 16, 2024

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2023 Results on Aug 16, 2023

Full year 2022 earnings released: EPS: CN¥2.68 (vs CN¥2.13 in FY 2021)

Investor sentiment improves as stock rises 16%

No independent directors

Third quarter 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.59 in 3Q 2021)

Investor sentiment improved over the past week

Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) intends to acquire Zhejiang Huafang Medical Care Co., Ltd from Holley Group Company Limited, Zhejiang Holley Investment Management Co., Ltd. and Suzhou Yuanyi Zhiyuan Equity Investment Partnership (Limited Partnership) for CNY 15.2 million.

Second quarter 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.64 in 2Q 2021)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.45 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.25 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.60 in FY 2019)

Jianmin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 16, 2021

Investor sentiment improved over the past week

New 90-day low: CN¥24.68

Third quarter earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day high - CN¥23.96

First half earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 13, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media